Industry has done a remarkable job funding FDA’s generic drug user fee program during its first two years, yet a large portion of the funds are not directly supporting ANDA approvals or facility inspections.
Net fee collections during fiscal years 2013 and 2014 were $624.9 million, exceeding estimates by more than $20 million. Yet,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?